Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation |
Lim, Yun-Sook
(Laboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Jeonbuk National University)
Nguyen, Lap P. (Laboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Jeonbuk National University) Lee, Gun-Hee (Korea Zoonosis Research Institute, Jeonbuk National University) Lee, Sung-Geun (Korea Zoonosis Research Institute, Jeonbuk National University) Lyoo, Kwang-Soo (Korea Zoonosis Research Institute, Jeonbuk National University) Kim, Bumseok (College of Veterinary Medicine, Jeonbuk National University) Hwang, Soon B. (Laboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Jeonbuk National University) |
1 | Corbett, K.S., Flynn, B., Foulds, K.E., Francica, J.R., Boyoglu-Barnum, S., Werner, A.P., Flach, B., O'Connell, S., Bock, K.W., Minai, M., et al. (2020). Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544-1555. DOI |
2 | Machhi, J., Herskovitz, J., Senan, A.M., Dutta, D., Nath, B., Oleynikov, M.D., Blomberg, W.R., Meigs, D.D., Hasan, M., Patel, M., et al. (2020). The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J. Neuroimmune Pharmacol. 15, 359-386. DOI |
3 | Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Symonds, W.T., Hindes, R.G., and Berrey, M.M. (2013). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34-44. DOI |
4 | Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M.L., Lescure, F.X., et al. (2020). Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 382, 2327-2336. DOI |
5 | Reed, L.J. and Muench, H. (1938). A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497. |
6 | Law, G.L., Tisoncik-Go, J., Korth, M.J., and Katze, M.G. (2013). Drug repurposing: a better approach for infectious disease drug discovery? Curr. Opin. Immunol. 25, 588-592. DOI |
7 | Lim, Y.S., Mai, H.N., Nguyen, L.P., Kang, S.M., Tark, D., and Hwang, S.B. (2021). Adenosylhomocysteinase like 1 interacts with nonstructural 5A and regulates hepatitis C virus propagation. J. Microbiol. 59, 101-109. DOI |
8 | Mulligan, M.J., Lyke, K.E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K.A., et al. (2020). Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589-593. DOI |
9 | Park, C., Min, S., Park, E.M., Lim, Y.S., Kang, S., Suzuki, T., Shin, E.C., and Hwang, S.B. (2015). Pim kinase interacts with nonstructural 5A protein and regulates hepatitis C virus entry. J. Virol. 89, 10073-10086. DOI |
10 | Soumana, D.I., Ali, A., and Schiffer, C.A. (2014). Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem. Biol. 9, 2485-2490. DOI |
11 | Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.Y., et al. (2020). Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181, 894-904.e9. DOI |
12 | World Health Organization (2020). Coronavirus disease (COVID-19) situation reports. Retrieved December 8, 2020, from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ |
13 | Ghahremanpour, M.M., Tirado-Rives, J., Deshmukh, M., Ippolito, J.A., Zhang, C.H., de Vaca, I.C., Liosi, M.E., Anderson, K.S., and Jorgensen, W.L. (2020). Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med. Chem. Lett. 11, 2526-2533. DOI |
14 | Matsuyama, S., Nagata, N., Shirato, K., Kawase, M., Takeda, M., and Taguchi, F. (2010). Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 84, 12658-12664. DOI |
15 | Ciotti, M., Angeletti, S., Minieri, M., Giovannetti, M., Benvenuto, D., Pascarella, S., Sagnelli, C., Bianchi, M., Bernardini, S., and Ciccozzi M. (2019). COVID-19 outbreak: an overview. Chemotherapy 64, 215-223. DOI |
16 | Coleman, C.M. and Frieman, M.B. (2014). Coronaviruses: important emerging human pathogens. J. Virol. 88, 5209-5212. DOI |
17 | Cui, J., Li, F., and Shi, Z.L. (2019). Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181-192. DOI |
18 | Duan, L., Zheng, Q., Zhang, H., Niu, Y., Lou, Y., and Wang, H. (2020). The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens. Front. Immunol. 11, 576622. DOI |
19 | Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., Serrano-Wu, M.H., Langley, D.R., Sun, J.H., O'Boyle, D.R., 2nd, et al. (2010). Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96-100. DOI |
20 | Guy, R.K., Dipaola, R.S., Romanelli, F., and Dutch, R.E. (2020). Rapid repurposing of drugs for COVID-19. Science 368, 829-830. DOI |
21 | Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., Smith, E.C., Case, J.B., Feng, J.Y., Jordan, R., et al. (2018). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, e00221-18. |
22 | Choi, J.W., Kim, J.W., Nguyen, L.P., Nguyen, H.C., Park, E.M., Choi, D.H., Han, K.M., Kang, S.M., Tark, D., Lim, Y.S., et al. (2020). Nonstructural NS5A protein regulates LIM and SH3 domain protein 1 to promote hepatitis C virus propagation. Mol. Cells 43, 469-478. DOI |
23 | Warren, T.K., Jordan, R., Lo, M.K., Ray, A.S., Mackman, R.L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H.C., et al. (2016). Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381-385. DOI |
24 | Woo, P.C., Huang, Y., Lau, S.K., and Yuen, K.Y. (2010). Coronavirus genomics and bioinformatics analysis. Viruses 2, 1804-1820. DOI |
25 | Yousefi, H., Mashouri, L., Okpechi, S.C., Alahari, N., and Alahari, S.K. (2021). Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: a review describing drug mechanisms of action. Biochem. Pharmacol. 183, 114296. DOI |
26 | Zhou, Y., Wang, F., Tang, J., Nussinov, R., and Cheng, F. (2020). Artificial intelligence in COVID-19 drug repurposing. Lancet Digit. Health 2, e667-e676. DOI |
27 | Chu, D.K.W., Pan, Y., Cheng, S.M.S., Hui, K.P.Y., Krishnan, P., Liu, Y., Ng, D.Y.M., Wan, C.K.C., Yang, P., Wang, Q., et al. (2020). Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin. Chem. 66, 549-555. DOI |
28 | Sheahan, T.P., Sims, A.C., Graham, R.L., Menachery, V.D., Gralinski, L.E., Case, J.B., Leist, S.R., Pyrc, K., Feng, J.Y., Trantcheva, I., et al. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653. DOI |
29 | Suzuki, Y., Ikeda, K., Suzuki, F., Toyota, J., Karino, Y., Chayama, K., Kawakami, Y., Ishikawa, H., Watanabe, H., Hu, W., et al. (2013). Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J. Hepatol. 58, 655-662. DOI |
30 | Trivedi, J., Mohan, M., and Byrareddy, S.N. (2020). Drug repurposing approaches to combating viral infections. J. Clin. Med. 9, 3777. DOI |
31 | Hassan, A.O., Kafai, N.M., Dmitriev, I.P., Fox, J.M., Smith, B.K., Harvey, I.B., Chen, R.E., Winkler, E.S., Wessel, A.W., Case, J.B., et al. (2020). A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169-184.e13. DOI |
32 | Lefkowitz, E.J., Dempsey, D.M., Hendrickson, R.C., Orton, R.J., Siddell, S.G., and Smith, D.B. (2018). Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res. 46(D1), D708-D717. DOI |
33 | Lim, Y.S. and Hwang, S.B. (2011). Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J. Biol. Chem. 286, 11290-11298. DOI |
34 | Lim, Y.S., Tran, H.T., Park, S.J., Yim, S.A., and Hwang, S.B. (2011). Peptidylprolyl isomerase Pin1 is a cellular factor required for hepatitis C virus propagation. J. Virol. 85, 8777-8788. DOI |
35 | Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R., Reindollar, R., Rustgi, V., McPhee, F., Wind-Rotolo, M., et al. (2012). Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216-224. DOI |
36 | Manfredonia, I. and Incarnato, D. (2021). Structure and regulation of coronavirus genomes: state-of-the-art and novel insights from SARS-CoV-2 studies. Biochem. Soc. Trans. 49, 341-352. DOI |
37 | Murakami, E., Tolstykh, T., Bao, H., Niu, C., Steuer, H.M., Bao, D., Chang, W., Espiritu, C., Bansal, S., Lam, A.M., et al. (2010). Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 285, 34337-34347. DOI |
38 | Nettles, R.E., Gao, M., Bifano, M., Chung, E., Persson, A., Marbury, T.C., Goldwater, R., DeMicco, M.P., Rodriguez-Torres, M., Vutikullird, A., et al. (2011). Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54, 1956-1965. DOI |